These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7094664)

  • 21. Rifampicin in the treatment of tuberculous meningitis.
    Girgis NI; Yassin MW; Laughlin LW; Edman DC; Farid Z; Watten RH
    J Trop Med Hyg; 1978 Dec; 81(12):246-7. PubMed ID: 748569
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [1,200 mg rifampicin(Rimactan) as an oral one-dose treatment of uncomplicated gonorrhea in women].
    Schwarzenbach HR; Rufli T; Glaus L; Bergamini N
    Dermatologica; 1983; 167(5):262-6. PubMed ID: 6653852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Leucopenia caused by two rifampicin preparations.
    van Assendelft AH
    Eur J Respir Dis; 1984 May; 65(4):251-8. PubMed ID: 6723834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical findings of cefoxitin in the treatment of serious infections and the prevention of postoperative infections (author's transl)].
    Ito H; Uno E; Ikeda M; Shimoji T; Higashi S; Yamamoto S
    Jpn J Antibiot; 1981 Sep; 34(9):1307-12. PubMed ID: 7328753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study on ceftazidime in the field of pediatrics].
    Minamitani M; Hachimori K; Kaneda K
    Jpn J Antibiot; 1984 Mar; 37(3):377-88. PubMed ID: 6376851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and a rifampicin-containing antituberculosis regimen.
    Lopez-Cortes LF; Ruiz-Valderas R; Ruiz-Morales J; Leon E; de Campos AV; Marin-Niebla A; Marquez-Solero M; Lozano F; Valiente R
    J Antimicrob Chemother; 2006 Nov; 58(5):1017-23. PubMed ID: 16956905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cefmetazole in the treatment of bacterial infections in the newborn (author's transl)].
    Kobayashi Y; Haruta T; Morikawa Y; Kuroki S; Okura K; Fujiwara T
    Jpn J Antibiot; 1980 Nov; 33(11):1237-46. PubMed ID: 6941035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Penetration of parenterally administered rifampicin into bone tissue.
    Roth B
    Chemotherapy; 1984; 30(6):358-65. PubMed ID: 6518835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bacteriological, pharmacokinetic and clinical studies on aztreonam in the pediatric field. Pediatric Study Group of Aztreonam].
    Fuyii R; Meguro H; Arimasu O; Sunakawa K; Ishizuka Y; Nakazawa S; Sato H; Narita A; Matsumoto K; Suzuki H
    Jpn J Antibiot; 1985 Nov; 38(11):3195-216. PubMed ID: 3912524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experimental and clinical studies on 6059-S (author's transl)].
    Toyonaga Y; Sugita M; Kurosu Y; Kumagai K; Hori M; Takahashi T
    Jpn J Antibiot; 1981 May; 34(5):764-81. PubMed ID: 6457175
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum and urine concentrations of rifampicin administered by intravenous infusion in man.
    Acocella G; Bonollo L; Mainardi M; Margaroli P; Tenconi LT
    Arzneimittelforschung; 1977; 27(6):1221-6. PubMed ID: 578447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of cefotiam in pediatric field (author's transl)].
    Iwai N; Sasaki A; Taneda Y; Inokuma K
    Jpn J Antibiot; 1981 Jun; 34(6):1002-18. PubMed ID: 6270417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
    Engbaek HC; Heckscher T; Højgaard C; Larsen SO; Rasmussen KN; Vergmann B
    Eur J Respir Dis; 1982 Mar; 63(2):84-93. PubMed ID: 7040100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation on ceftriaxone in the pediatric field].
    Nakazawa S; Satoh H; Niino K; Hirama Y; Narita A; Suzuki H; Nakazawa S; Chikaoka H; Tazoe K
    Jpn J Antibiot; 1984 Nov; 37(11):2083-101. PubMed ID: 6098703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
    Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M
    J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily ceftriaxone in the outpatient treatment of paediatric infections.
    Bradley JS
    Chemotherapy; 1991; 37 Suppl 3():3-6. PubMed ID: 1884651
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections.
    Saballs M; Pujol M; Tubau F; Peña C; Montero A; Domínguez MA; Gudiol F; Ariza J
    J Antimicrob Chemother; 2006 Sep; 58(3):697-700. PubMed ID: 16895941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fundamental and clinical studies of aspoxicillin in the pediatric field].
    Motohiro T; Kawakami A; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Tominaga K
    Jpn J Antibiot; 1985 Jul; 38(7):1951-71. PubMed ID: 4068228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term intravenous rifampicin treatment. Advantages and disadvantages.
    Anker N; Band FC
    Eur J Respir Dis; 1981; 62(2):84-6. PubMed ID: 6453721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
    Sunpath H; Winternheimer P; Cohen S; Tennant I; Chelin N; Gandhi RT; Murphy RA
    Int J Tuberc Lung Dis; 2014 Jun; 18(6):689-93. PubMed ID: 24903940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.